輝瑞股東在公司宣佈連續第 350 次發放股利後舉行會議
Pfizer shareholders meet after announcing 350th consecutive dividend
在2026年4月，輝瑞公司( Pfizer Inc.)
In April 2026, Pfizer Inc. celebrated a major corporate milestone as its board of directors announced a $0.43 per share dividend.
慶祝了一個重大的企業里程碑，其董事會宣布每股發放0.43美元的股利。
This marks the 350th consecutive quarterly payment, reflecting 56 years of financial consistency.
這一成就於2026年股東周年大會上受到矚目，領導層在會中平衡了為投資者提供穩定收入的說法與公司積極的成長策略。
While the impressive 6.3% dividend yield appeals to income-focused shareholders, Pfizer is simultaneously navigating a complex transition.
儘管6.3%的股息殖利率吸引了注重收入的股東，但輝瑞正同時經歷一項複雜的轉型。
The company remains deeply invested in its clinical pipeline, including the promising MEVPRO-1 Phase 3 trial for prostate cancer, while managing regulatory challenges and market fluctuations.
公司持續深耕其臨床研發管線，包括針對攝護腺癌前景看好的MEVPRO-1第三期臨床試驗，同時應對監管挑戰與市場波動。
Analysts remain divided on the stock; some see the long-term dividend history as a sign of institutional strength, while others focus on the volatility inherent in the pharmaceutical sector.
分析師對該股票看法分歧；有些人將長期的股息紀錄視為機構實力的象徵，而另一些人則關注製藥產業固有的波動性。
Ultimately, Pfizer faces the ongoing task of maintaining its legacy of rewarding long-term shareholders while successfully navigating a competitive, innovation-driven landscape to ensure future revenue growth.
最終，輝瑞面臨的持續任務是在成功應對競爭激烈且以創新為導向的環境，以確保未來營收成長的同時，維持其回饋長期股東的傳統。
